10/20/2005 1:01:51 PM ET


    SWISS MEDICA’S UNIQUE O24 FIBROMYALGIA™ IS NOW AVAILABLE IN OVER 5,000 RETAIL STORES AND
    EXPECTS IT TO BE SOLD IN MORE THAN 10,000 STORES BEFORE YEAR-END
      
    FOR IMMEDIATE RELEASE

    Stock Symbol: OTC BB: SWME
    October 20, 2005

    SWISS MEDICA’S UNIQUE O24 FIBROMYALGIA™ IS NOW AVAILABLE IN OVER 5,000 RETAIL STORES AND
    EXPECTS IT TO BE SOLD IN MORE THAN 10,000 STORES BEFORE YEAR-END

    Toronto, Canada - Swiss Medica, Inc. (OTCBB: SWME) is pleased to announce that over 5,000 retail stores are
    now selling O24 Fibromyalgia™ throughout the United States. In addition, the Company expects O24
    Fibromyalgia™ to be available in more than 10,000 stores before year-end. O24 Fibromyalgia™ is the only over-
    the-counter or prescription product, that has been clinically shown to relieve fibromyalgia pain and carries the
    National Fibromyalgia Association’s coveted “seal of approval”. Up to 11-million Americans who suffer from
    fibromyalgia now have a solution for their pain. For detailed store availability, please see the store locator at
    www.O24zone.com/retailers.html

    What is Fibromyalgia?

    Fibromyalgia (FM) is an increasingly recognized chronic pain illness which is characterized by widespread
    musculoskeletal aches, pain and stiffness, soft tissue tenderness, general fatigue and sleep disturbances. The
    most common sites of pain include the neck, back, shoulders, pelvic girdle and hands, but any body part can be
    involved. Fibromyalgia patients experience a range of symptoms of varying intensities that wax and wane over
    time. According to the National Fibromyalgia Association, it is estimated that approximately 3-6% of the U.S.
    population has FM. Although a higher percentage of women are affected, it does strike men, women and
    children of all ages and races. Because of its debilitating nature, Fibromyalgia has a serious impact on patients'
    family, friends, and employers, as well as society at large.

    About Swiss Medica, Inc.

    Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
    market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a
    world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
    visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com

    Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
    relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by
    healthcare professionals and athletes in the United States, Canada and in Europe. O24™ is widely available
    throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit
    www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

    Swiss Medica is launching the patented O24 Fibromyalgia™ pain reliever (US Patent #6,444,238B1) over-the-
    counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently
    awarded O24 Fibromyalgia™ their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the
    long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of
    the patients who used O24 Fibromyalgia™ reported mild to markedly better improvement, versus only 7 per cent
    who used the placebo. Customers can visit www.O24zone.com for information on O24 Fibromyalgia™ and to
    order the product online.

    Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS
    Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce
    changes in mood and appetite that women experience during the premenstrual period. Customers can also visit:
    www.pmsescape.com for additional information and ordering details.

    Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United
    States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
    statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
    transactions being contemplated, risks related to international sales and potential foreign currency exchange
    fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
    changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
    periodic reports filed with the United States Securities and Exchange Commission and other regulatory
    authorities.

    For more information, please contact:

    Swiss Medica Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    djones@swissmedica.com